KIAA0319L Knockout Jurkat Polyclonal Cells are a ready-to-use CRISPR/Cas9-edited polyclonal population of Jurkat T lymphocytes with disrupted KIAA0319L expression. KIAA0319L encodes the adeno-associated virus receptor (AAVR), a primary mediator of AAV cellular entry. This polyclonal pool avoids single-cell cloning biases and provides a reliable loss-of-function model for studying AAVR-dependent endocytosis and transduction.
The Jurkat host cell line is an immortalized human T lymphocyte derived from a patient with acute T-cell leukemia. Widely utilized for modeling T-cell activation, signaling, and HIV infection, Jurkat cells are particularly suited for investigating viral entry mechanisms in an immune-relevant context. Their robust growth and amenability to genetic modification make them an ideal platform for generating AAV receptor knockout models.
KIAA0319L functions as the principal receptor for adeno-associated viruses, binding viral capsid proteins through its polycystic kidney disease (PKD) domains. Ligand engagement triggers clathrin-mediated endocytosis via association with clathrin adaptor AP-2 and dynamin. The virus-receptor complex is routed into the endosomal pathway, sequentially marked by Rab5 and EEA1 on early endosomes, then trafficked through Rab7-positive compartments to the trans-Golgi network (TGN46). KIAA0319L also interacts with GPR108, the retromer complex, and the nuclear pore component Nup358, facilitating nuclear import and subsequent transgene expression. These interactions position KIAA0319L as a critical trafficking hub for AAV.
Disrupting KIAA0319L in Jurkat cells ablates AAV binding and entry, providing a rigorous system to dissect T-cell-specific transduction requirements. This knockout tool enables discrimination between AAVR-dependent and independent entry pathways, assessment of serotype tropism, and validation of gene therapy vector targeting. As primary T cells are key targets for AAV-based immunotherapies, this model offers translational relevance for optimizing vector design and overcoming barriers to efficient gene delivery.
Researchers can apply these cells in flow cytometric quantification of AAV transduction, immunofluorescence-based trafficking assays, co-immunoprecipitation of AAVR?Ccapsid interactions, and endocytosis inhibitor studies. The polyclonal pool also supports RNA-seq off-target analysis and serotype screens. This resource accelerates fundamental studies of viral endocytosis and applied development of AAV vectors for T-cell gene therapy. For further information or technical customization, reach out to Ascent Research.
